Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$355K Buy
6,432
+21
+0.3% +$1.14K 0.02% 352
2025
Q4
$314K Buy
6,411
+333
+5% +$15.5K 0.02% 370
2025
Q3
$262K Sell
6,078
-99
-2% -$3.87K 0.02% 416
2025
Q2
$237K Sell
6,177
-80
-1% -$3.06K 0.02% 430
2025
Q1
$242K Buy
+6,257
New +$229K 0.02% 379
2024
Q4
Sell
-6,173
Closed -$252K 453
2024
Q3
$252K Buy
6,173
+849
+16% +$34.7K 0.02% 347
2024
Q2
$205K Buy
5,324
+230
+5% +$9.68K 0.02% 357
2024
Q1
$218K Buy
+5,094
New +$210K 0.02% 342
2022
Q3
Sell
-4,202
Closed -$229K 215
2022
Q2
$229K Buy
+4,202
New +$232K 0.04% 172

Other funds holding GSK

PDS Planning's GSK Position: Q1 2026 in Review

PDS Planning increased its GSK (GSK) stake by 0.33% in Q1 2026, buying an estimated $1.14K and bringing the position to 6,432 shares worth $355K. The position accounts for 0.02% of the portfolio, ranked #352.

PDS Planning first reported a position in GSK in Q2 2022 and has held it in 9 quarters since. 1,032 funds tracked by Wall St. Rank hold GSK as of Q1 2026.

  • PDS Planning held 6,432 shares of GSK worth $355K as of Q1 2026.
  • PDS Planning bought 21 GSK shares in Q1 2026, an estimated $1.14K.
  • GSK made up 0.02% of PDS Planning's portfolio in Q1 2026, its #352 holding.
  • PDS Planning first reported a position in GSK in Q2 2022 and has held it in 9 quarters since.
  • 1,032 funds tracked by Wall St. Rank held GSK as of Q1 2026.

Based on PDS Planning's 13F filing for Q1 2026, filed 22 Apr 2026.